KMTS (Kestra Medical Technologies) ROCE %: -47.13% (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.24
! 4 Warning Signs
View Full Analysis

What is Kestra Medical Technologies ROCE %?

Kestra Medical Technologies KMTS -2.34% 10 ROCE % is -47.13% as of Jan. 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kestra Medical Technologies's annualized ROCE % for the quarter that ended in Jan. 2026 was -47.13%.

Kestra Medical Technologies  (NAS:KMTS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kestra Medical Technologies ROCE % Related Terms

Kestra Medical Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies ROCE % Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24
ROCE %
-760.15 -235.83 -608.52 -1,179.81

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.14 -120.46 -38.85 -55.46 -47.13
KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies ROCE % Calculation

Kestra Medical Technologies's annualized ROCE % for the fiscal year that ended in Apr. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2024 )  (A: Apr. 2023 )(A: Apr. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2024 )  (A: Apr. 2023 )(A: Apr. 2024 )
=-87.866/( ( (38.656 - 36.739) + (45.949 - 32.971) )/ 2 )
=-87.866/( (1.917+12.978)/ 2 )
=-87.866/7.4475
=-1,179.81 %

Kestra Medical Technologies's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-128.972/( ( (246.701 - 35.756) + (379.342 - 42.931) )/ 2 )
=-128.972/( ( 210.945 + 336.411 )/ 2 )
=-128.972/273.678
=-47.13 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.13% mean?
Kestra Medical Technologies (KMTS) has a ROCE % of -47.13% as of Jan. 2026.
Is Kestra Medical Technologies' ROCE % too high?
Kestra Medical Technologies' current ROCE % is -47.13%. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' ROCE % compare to ATRC and STAA?
Kestra Medical Technologies' ROCE % of -47.13% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current ROCE % is -47.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current ROCE % of -47.13%. The current ROCE % is -47.13%. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current ROCE % is -47.13% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.24
Price